|
SCHWARZ PHARMA, traditionally known as a cardiovascular specialist, has continuously expanded its range of indications and products. The company is mainly active in the field of prescription-only medicine. Concentrating on the therapeutic areas of the central nervous system, the cardiovascular system and urology SCHWARZ PHARMA develops and markets innovative drugs for unmet medical needs. SCHWARZ PHARMA AG is a public traded pharmaceutical company with global headquarters in Monheim, Germany. The company has a strong international presence with subsidiaries in Germany, Italy, Spain, France, Great Britain, Poland, North America, Asia and its licensing agreements in additionally 50 countries worldwide. Shares of SCHWARZ PHARMA AG are traded on the Frankfurt and Düsseldorf stock exchanges. Its ADR program is managed by the Bank of New York.
Activity:
- Manufacturing
Product / Technology type(s) covered:
- Pharmaceuticals / Therapeutics
- Prescription drugs (Rx)
Therapeutic targets:
- Cardiovascular
- Central nervous system
- Gastrointestinal
- Neurology
- Urology
|
|